source
- FDA issues draft guidance outlining data flexibilities for cell and gene therapy developersThe FDA released a draft guidance from its Center for Biologics Evaluation and Research (CBER) that clarifies how developers of cell and gene therapies can use existing data and prior knowledge in…
- NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…